Despite recent advances, immunotherapy in CRC patients is largely disappointing (62), in particular for APC gene-mutation initiated, microsatellite-stable (MSS) CRC (63, 64) which do not respond to checkpoint inhibitors (4, 65). The gene discussed is APC; the disease is colorectal carcinoma.